Evidence map›Paper›PMID 24607557›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2014

Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.

Ajay K Nooka, Heather R Johnson, Jonathan L Kaufman, Christopher R Flowers, Amelia Langston, Conor Steuer, Michael Graiser, Zahir Ali, Nishi N Shah, Sravanti Rangaraju and 4 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07709195 (Chlorophyllin as an Adjunct for Reducing Oral Mucositis in Myeloablative Total Body Irradiation), which is not on this map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07709195 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Chlorophyllin as an Adjunct for Reducing Oral Mucositis in Myeloablative Total Body Irradiation

TypeinterventionalSponsorTata Memorial CentreRan2024 to 2027Enrolled17ConditionsOral Mucositis, Total Body Irradiation, Hematological Malignancies, Hematopoietic Stem Cell Transplantation (HSCT)ArmsSodium Copper Chlorophyllin
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Article
  11. Cost burden of diffuse large B-cell lymphoma.Expert review of pharmacoeconomics & outcomes research · 2019
    Review
  12. Unlocking the Complex Flavors of Dysgeusia after Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Review
  13. Article
  14. CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Ajay K Nooka *Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Heather R Johnson *Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Jonathan L KaufmanDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Christopher R FlowersDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Amelia LangstonDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Conor SteuerDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Michael GraiserDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Zahir AliDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Nishi N ShahDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Sravanti RangarajuDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Dana NickleachBiostatistics & Bioinformatics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, GA.
Jingjing GaoBiostatistics & Bioinformatics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, GA.
Sagar LonialDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Edmund K WallerDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Emory University · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Translational Physician-Scientist Training Program in OncologyT32CA160040 · NCI · EMORY UNIVERSITY · PI SHIN, DONG M · 2013 to 2017
$1.2M
NCI NIH HHS P30 CA138292NCI NIH HHS P30CA138292NCI NIH HHS T32 CA160040
6 · The paper itself

Abstract

Trials have shown benefits of palifermin in reducing the incidence and severity of oral mucositis in patients with hematological malignancies undergoing autologous hematopoietic stem cell transplantation (HSCT) with total body irradiation (TBI)-based conditioning regimens. Similar outcome data are lacking for patients receiving non-TBI-based regimens. We performed a retrospective evaluation on the pharmacoeconomic benefit of palifermin in the setting of non-TBI-based conditioning and autologous HSCT. Between January 2002 and December 2010, 524 patients undergoing autologous HSCT for myeloma (melphalan 200 mg/m²) and lymphoma (high-dose busulfan, cyclophosphamide, and etoposide) as preparative regimen were analyzed. Use of patient-controlled analgesia (PCA) was significantly lower in the palifermin-treated groups (myeloma: 13% versus 53%, P < .001; lymphoma: 46% versus 68%, P < .001). Median total transplant charges were significantly higher in the palifermin-treated group, after controlling for inflation (myeloma: $167,820 versus $143,200, P < .001; lymphoma: $168,570 versus $148,590, P < .001). Palifermin treatment was not associated with a difference in days to neutrophil engraftment, length of stay, and overall survival and was associated with an additional cost of $5.5K (myeloma) and $14K (lymphoma) per day of PCA avoided. Future studies are suggested to evaluate the cost-effectiveness of palifermin compared with other symptomatic treatments to reduce transplant toxicity using validated measures for pain and quality of life.

Indexed as

AdolescentAdultAgedEconomics, PharmaceuticalFemaleFibroblast Growth Factor 7Hematopoietic Stem Cell TransplantationHumansLymphomaMaleMiddle AgedMucositisMultiple MyelomaRetrospective StudiesTransplantation, AutologousTransplantation ConditioningFibroblast Growth Factor 7MucositisPaliferminPharmacoeconomic analysisRecombinant human keratinocyte growth factor

Identifiers

PMID24607557
PMCPMC4063211
OpenAlexW2071844203

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.